Breaking News
Get 55% Off 0
NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stock
Read More
Close

Axa Framlington Biotech Fund - Z Accumulation (0P0000XMRD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.392 +0.080    +1.41%
22/11 - Closed. Currency in GBP
Type:  Fund
Market:  United Kingdom
Issuer:  AXA Equitable
ISIN:  GB00B784NS11 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 333.87M
AXA Framlington Biotech Fund GBP Z Acc 5.392 +0.080 +1.41%

0P0000XMRD Overview

 
On this page you'll find an in-depth profile of Axa Framlington Biotech Fund - Z Accumulation. Learn about the key management, total assets, investment strategy and contact information of 0P0000XMRD among other information.
Category

Sector Equity Biotechnology

Total Assets

333.87M

Expenses

0.83%

Inception Date

Apr 16, 2012

Contact Information

Address 100, Esplanade du Général de Gaulle
Paris, 92932
France
Phone +33 1 44 45 70 00
Fax Paris

Top Executives

Name Title Since Until
Chris Eccles Research Analyst 2024 Now
Biography Chris Eccles is a research analyst who specialises in testing and regulatory affairs. He researches stocks globally and focuses on the Healthcare sector. Chris joined Impax in March 2019. He started working in the financial industry in 2011 as a research analyst at Morgan Stanley where he focused on European large-cap pharmaceuticals. In 2014, he became a partner at the hedge fund Kola Capital where he worked as a global equities analyst for three years before moving to Stifel in 2017 to work as a Healthcare Specialist. Chris achieved an MA (Oxon) Physiological Sciences First Class Honours, from the University of Oxford.
Cinney Zhang - 2024 Now
Catherine Tennyson - 2024 Now
Cinney Zhang - 2023 2024
Linden Thomson - 2012 2024
Peter Hughes Portfolio Manager 2001 2023
Biography Peter joined Redwheel in July 2023 as a Partner and Portfolio Manager. He will manage the Redwheel Life Changing Treatments strategy. His ambition for the role is to focus on improving patients’ lives, regardless of where they live by investing in companies facilitating improved health care outcomes while providing long-term capital appreciation for investors. Before Redwheel, Peter was Portfolio Manager of the AXA World Funds Longevity Economy fund and AXA Framlington Health fund, specialising in healthcare. Before this, he held appointments at Architas, in roles covering investment research and relationship management. Peter holds a PhD in biochemistry from University College London. He has a master's degree in chemistry from the University of Surrey and is a CFA Charterholder. He is also an ambassador for the Royal Marsden Cancer Charity. Peter was named as a 2021 Rising Star of Asset Management by Financial News.
Dani Saurymper - 2015 2020
Biography Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare.
Gemma Game - 2011 2015
Deane Donnigan clinical Specialist 2010 2011
Biography Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen.
Andy Smith Portfolio manager 2009 2010
Biography Andy joined AXA Framlington in April 2008 as Portfolio Manager within the healthcare team with specific responsibility for the AXA Framlington Biotech Fund. Previously, he spent three years at SV Life Sciences where he was responsible for managing a global biotechnology investment fund. From 2004 to 2005 he worked at Schroders as Director and Fund Manager, Global Equities. Between 2002 and 2004 he worked within the Asset Management division of the 3i Group as Investment Manager and then Director.
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0000XMRD Comments

Write your thoughts about Axa Framlington Biotech Fund - Z Accumulation
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email